Commentary Open Access
Mechanistic Drivers, Translational Gaps, and Modeling Approaches for Ocular Adverse Events in Antibody–Drug Conjugate Therapy
Terezinha de Souza1, Ping Peng2, Rudy Gunawan3, Jenna Voellinger3, Haley D. Neff-LaFord3, Iris C.R.M. Kolder1, Chaitali Passey2, Summer Feng2,*, Jeffrey R. Harris2
- 1Genmab B.V., Utrecht, Netherlands
- 2Genmab US, Inc., Plainsboro, NJ, USA
- 3Pfizer Inc., Bothell, WA, USA
Corresponding Author
Summer Feng, sufe@genmab.com
Received Date: May 01, 2026
Accepted Date: July 09, 2026
de Souza T, Peng P, Gunawan R, Voellinger J, Neff-LaFord HD, Kolder ICRM, et al. Mechanistic Drivers, Translational Gaps, and Modeling Approaches for Ocular Adverse Events in Antibody–Drug Conjugate Therapy. J Cancer Immunol. 2026;8(2):64–71.
Copyright: © 2026 de Souza T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Antibody Drug Conjugate Therapy, Cancer therapy, Ocular toxicity
Recommended Articles
SHP2 Inhibition as a Promising Anti-cancer Therapy: Function in Tumor Cell Signaling and Immune Modulation
The protein tyrosine phosphatase SHP2, encoded by PTPN11, functions as a critical signal transduction regulator and interacts with key signaling molecules in both RAS/ERK and PD-1/PD-L1/ BTLA (B- and T-lymphocyte attenuator) pathways. Targeting SHP2 pharmacologically, therefore, may be a promising therapeutic strategy for many RAS-driven cancers.
Immunogenic Cell Death: A Step Ahead of Autophagy in Cancer Therapy
Cell Death has long been considered to be an inevitable part of the life cycle of a cell and hence, considered a familiar consequence of cellular life.
Mechanism, Challenges, and Progresses of Chimeric Antigen Receptors T-cell Cancer Therapy
Cancer is a deadly disease and affects everyone at any level of age. Many people lose hope once they are diagnosed with cancer. This is because there is no effective treatment for it. Till the end of the 19th century, researchers across the world were eager to design effective remedies for this decapitating phenomenon and designed so many interventions even though nothing is compensatory for a malignant tumor; in some cases, the side effects overwhelm the benefits.